JAMA Oncology Author Interviews

JAMA Network
  • 3.8（11則評分）
  • 醫學
  • 每月更新

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

  1. Proportional Sedation for Persistent Agitated Delirium in Palliative Care

    7月31日

    Proportional Sedation for Persistent Agitated Delirium in Palliative Care

    Interview with David Hui, MD, and Eduardo Bruera, MD, authors of Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Proportional Sedation for Persistent Agitated Delirium in Palliative Care

    18 分鐘
  2. New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance

    5月29日

    New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance

    Interview with Thorir Einarsson Long, MD, PhD, and Ola Landgren, MD, PhD, authors of New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance. Hosted by Vivek Subbiah, MD. Related Content: New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance

    19 分鐘
  3. Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury

    4月24日

    Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury

    Interview with Shruti Gupta, MD, MPH, author of Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury. Hosted by Vivek Subbiah, MD. Related Content: Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury

    12 分鐘
  4. Accelerated Aging in Survivors of Childhood Cancer

    3月20日

    Accelerated Aging in Survivors of Childhood Cancer

    Interview with Jennifer M. Yeh, PhD, and Lisa R. Diller, MD, authors of Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions. Hosted by Vivek Subbiah, MD. Related Content: Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer

    19 分鐘
  5. Academic-Community Partnership and Deaths in Promyelocytic Leukemia

    2月27日

    Academic-Community Partnership and Deaths in Promyelocytic Leukemia

    Interview with Anand P. Jillella, MD, author of Academic-Community Partnership and Deaths in Promyelocytic Leukemia: The Nonrandomized ECOG-ACRIN EA9131 Trial. Hosted by Vivek Subbiah, MD. Related Content: Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality

    19 分鐘
  6. Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy

    1月30日

    Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy

    Interview with Michael A. Postow, MD, author of Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy. Hosted by Vivek Subbiah, MD. Related Content: Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy

    12 分鐘
  7. Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020

    2024/12/05

    Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020

    Interview with Katrina A. B. Goddard, PhD, author of Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. Hosted by Vivek Subbiah, MD. Related Content: Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020

    16 分鐘
  8. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

    2024/11/21

    Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

    Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

    19 分鐘
顯示全部 (126)

評分與評論

3.8
（滿分 5 顆星）
11 則評分

簡介

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

資訊

  • 頻道
    JAMA Network
  • 創作者
    JAMA Network
  • 活躍年代
    2017年 - 2025年
  • 集數
    126
  • 年齡分級
    兒少適宜
  • 版權
    © 2024 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.
  • 節目網站
    JAMA Oncology Author Interviews

「JAMA Network」的更多內容

你可能也會喜歡